A previous study demonstrated that FDA-approved nintedanib for Idiopathic Pulmonary Fibrosis (IPF) therapy could downregulate FKBP10 expression in IPF fibroblasts.15 The gene discussed is FKBP10; the disease is idiopathic pulmonary fibrosis.